Explore the August issue of The American Journal of Gastroenterology!
Featuring How I Approach It articles:
💨 Bloating & Breath Tests: A Pragmatic Approach
🔎 Reporting Esophageal Manometry Findings
📕https://t.co/0M4HCpiML3
@JasmohanBajaj@MLongMD
Call for Papers—AJG Special Issue: 🧠Gut-Brain Interactions Across Digestive and Liver Diseases
Submission window closes December 15, 2026
📕 https://t.co/D18mPzXt2c
@JasmohanBajaj@MLongMD
Spray Cryotherapy Esophageal Consortium Consensus Recommendations for Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus and Esophageal Cancer Using a Modified Delphi Process
Shah, et al.
📕 https://t.co/iV44nctGm4
ACG proudly welcomes the 2026–2027 ACG Case Reports Journal Editorial Board!
Co-EICs Dr. Arjun Chatterjee and Dr. Linda Jiang will lead a talented group of Associate Editors and Social Media Ambassadors. Join us in congratulating the new Board! 🎉
Patients Included in Clinical Trials of Biological Drugs for Inflammatory Bowel Disease Do Not Represent the Real-World Population
Casas Deza, et al.
📕 https://t.co/bPvOE6PceF
Review: Adenomatous Polyposis Coli Gene Polyposis-Related Syndromes
Jennifer K. Maratt, MD, MS; Anneleise Frie, MD & Jennifer M. Weiss, MD, MS
📕 https://t.co/xPrS7WG8uW
Distinct Clinical Phenotypes in Lactase Nonpersistence: Symptomatic, Asymptomatic, and Gassy-Asymptomatic
Azimov & Cohen-Michnik, et al.
📕 https://t.co/bENel7VJCJ
The Red Section: Practical Considerations for the Use of Semaglutide in MASH
Matthew A. Odenwald, MD, PhD & Mary E. Rinella, MD, FACG
📕 https://t.co/yxrftuZyn8
Fatty Pancreas Disease and the Risk of Future Diseases of the Exocrine Pancreas: A US Matched Cohort Study
Chatterjee, et al.
📕 https://t.co/pHX2PuxbNP
Avoidant/Restrictive Eating in People With and Without Bowel Symptoms in the General Population: Prevalence, Clinical Profile, and Associated Factors
Blomsten, et al.
📕
Normalization of Dyssynergic Bear Down Patterns in the Seated Position Predicts Normal Balloon Expulsion Testing on High-Resolution Anorectal Manometry
Wang, et al.
📕
Switching to Entecavir >3 Months Before the End of Tenofovir-Based Therapy in Hepatitis B e Antigen-Negative Patients May Reduce Early Relapse and Hepatitis Flare
Chen, et al.
📕